Additionally, the study sought to describe the genomic alterations found in these patients.<h4>Methods</h4>This national, multicenter, prospective study included adult patients diagnosed with advanced/metastatic NSCLC undergoing first line treatment with molecular diagnostic wild-type (or unknown) for at least ALK, EGFR, and ROS-1 genes under clinical practice conditions. This evidence concerns the gene ALK and non-small cell lung carcinoma.